{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:40:46Z","timestamp":1790293246187,"version":"4.1.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.1001\/jamadermatol.2026.1882","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:33:25Z","timestamp":1782920005000},"page":"773","source":"Crossref","is-referenced-by-count":3,"title":["GLP-1 Receptor Agonists in Hidradenitis Suppurativa\u2014Emerging Opportunities for Comorbidity Management?"],"prefix":"10.1001","volume":"162","author":[{"given":"Haley B.","family":"Naik","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Thiara","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ded260008r1","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"ded260008r2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jaad.2019.06.016","article-title":"All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States.","volume":"81","author":"Reddy","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ded260008r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.1907","article-title":"GLP-1 receptor agonist use and clinical outcomes in patients with hidradenitis suppurativa.","author":"Jastrzab-Miskiewicz","journal-title":"JAMA Dermatol"},{"issue":"6","key":"ded260008r4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"ded260008r5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"ded260008r6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ded260008r7","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control.","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"4","key":"ded260008r8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1.","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"ded260008r9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials.","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ded260008r10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis.","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"ded260008r11","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/dom.70440","article-title":"Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.","volume":"28","author":"Tan","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"ded260008r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity.","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2851183\/jamadermatology_naik_2026_ed_260008_1786734801.35511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:00:24Z","timestamp":1787151624000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2851183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1882","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}